A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

NCT00651664 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
59
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Millennium Pharmaceuticals, Inc.